SNM SCANcast: Bioscan offers advanced SPECT/CT preclinical scanner
In an audio interview with Victor Tchiprout, director of sales and marketing for Bioscan, hear how combining an advanced SPECT collimation system with a four-detector gantry promises improved image quality -- and how this could speed new drug development.
The development of SPECT and PET systems for preclinical imaging has resulted in major advances in nuclear medicine over the past 20 years, according to Simon R. Cherry, director of the Center for Molecular and Genomic Imaging at the University of California, Davis. The availability of such systems not only minimizes the sacrifice of laboratory animals, it increases the validity of research by allowing the long-term study of animal subjects. One device, the NanoSPECT/CT, featured at the 2006 Society of Nuclear Medicine meeting, raises the molecular imaging of rodents to a new level, according to Victor Tchiprout, director of sales and marketing for Bioscan, a Washington, D.C.-based developer of advanced instrumentation for the synthesis and detection of radiolabeled compounds. Hear how combining an advanced SPECT collimation system with a four-detector gantry promises improved image quality - and how this could speed new drug development.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
